Shareholders of Hao Tian International Construction Investment Group (HKG:1341) and its controlling shareholder Aceso Life Science (HKG:0474) will meet March 18 to vote on a proposed share placement by the former, a Tuesday filing with the Hong Kong bourse said.
Hao Tian International Construction, in October, had agreed to place 1,524,224,000 shares to at least six placees to raise around HK$600 million.
Assuming full completion, Aceso Life Science's stake in Hao Tian International Construction will be diluted from roughly 29.05% to 24.2%.
The dilution will constitute a deemed disposal since Hao Tian International Construction Investment will no longer be considered a unit of Aceso Life Science and the financial results of the former will no longer be consolidated in the financial statements of the latter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.